871123-98-7

Basic information

• Product Name: (2S,3S)-2-Amino-3-benzylsuccinic ammonium salt, DL-TBOA
• Synonyms: (2S,3S)-2-Amino-3-benzylsuccinic ammonium salt, DL-TBOA;L-β-threo-benzyl-aspartate ammonium salt;(2S,3S)-2-Amino-3-benzylsuccinic acid;L-β-threo-benzyl-aspartate;(3S)-3-(Phenylmethyl)-L-aspartic acid
• CAS NO: 871123-98-7
• Molecular Formula: C11H13NO4
• Molecular Weight: 223.23
• Mol File: 871123-98-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (2S,3S)-2-Amino-3-benzylsuccinic ammonium salt, DL-TBOA(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3S)-2-Amino-3-benzylsuccinic ammonium salt, DL-TBOA(871123-98-7)
• EPA Substance Registry System: (2S,3S)-2-Amino-3-benzylsuccinic ammonium salt, DL-TBOA(871123-98-7)

Safety Data

• Hazardous Substances Data: 871123-98-7(Hazardous Substances Data)

Upstream product

• 99477-50-6 2-Amino-3-benzyl-succinic acid 
• 885357-46-0 dimethyl N-tritylamino-β-benzylaspartate 

Relevant articles and documents

Structure-guided engineering of: Pseudomonas dacunhae l-aspartate β-decarboxylase for l-homophenylalanine synthesis

Structure-guided engineering of Pseudomonas dacunhael-aspartate β-decarboxylase (AspBDC) resulted in a double mutant (R37A/T382G) with remarkable 15400-fold improvement in specific activity reaching 216 mU mg-1, towards the target substrate 3(R)-benzyl-l-aspartate. A novel strategy for enzymatic synthesis of l-homophenylalanine was developed by using the variant as a biocatalyst affording 75% product yield within 12 h. Our results underscore the potential of engineered AspBDC for the biocatalytic synthesis of pharmaceutically relevant and value added unnatural l-amino acids.

Synthesis and preliminary pharmacological evaluation of novel derivatives of l-β-threo-benzylaspartate as inhibitors of the neuronal glutamate transporter EAAT3

A series of β-benzylaspartate derivatives were prepared from N-trityl-l-aspartate dimethyl ester and evaluated as inhibitors of neuronal glutamate transporter EAAT3. The result of the structure-activity studies suggests that the position occupied by the aromatic ring of β-benzylaspartate within the binding site of EAAT3 may be different from that occupied by comparable groups in previously identified inhibitors, such as l-threo-benzyloxy aspartate (TBOA). Further, halogen substitutions at the 3-postition of the aromatic ring of β-benzylaspartate can increase the potency with which the analogues inhibit EAAT3.

3-alkylaryl aspartate compounds and their use for selective enhancement of synaptic transmission

The present invention provides an L-aspartate derivative compound represented by the following structure wherein Ar represents an aromatic group; L represents a linking moiety; R represents hydrogen, alkyl, aryl, or heteroaryl; and indicates that the stereochemistry at the 3-position can be R or S. The compounds of the invention are useful for selectively inhibiting EAAT3 and for enhancing synaptic transmission. Additionally, the inventive compounds can be used to treat a patient suffering from Alzheimers disease or a neuropathy or a neurodegenerative disease in which L-glutamate transporter activity is involved in the onset of the disease.